Skip to content

G&A at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$11.46M+24.6%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$24.39M+53.1%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$28.24M+137%
Cytokinetics logo
CytokineticsCYTK
$91.72M+47.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$13.28M+13.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.98M-0.7%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's G&A?
Scholar Rock (SRRK) reported G&A of $50.2M in Q1 2026.
How has Scholar Rock's G&A changed year-over-year?
Scholar Rock's G&A increased by 76.7% year-over-year, from $28.41M to $50.2M.
What is the long-term trend for Scholar Rock's G&A?
Over 4 years (2021 to 2025), Scholar Rock's G&A has grown at a 44.6% compound annual growth rate (CAGR), from $40.27M to $176.21M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.